Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – What’s Next?

Oculis Holding AG (NASDAQ:OCS) saw strong trading volume on Friday . 1,115,990 shares changed hands during trading, an increase of 212% from the previous session’s volume of 357,595 shares.The stock last traded at $23.4510 and had previously closed at $29.65.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright upped their target price on shares of Oculis from $44.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. upped their target price on shares of Oculis from $38.00 to $42.00 and gave the company an “overweight” rating in a report on Monday, May 18th. Stifel Nicolaus upped their target price on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Finally, Needham & Company LLC upped their target price on shares of Oculis from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and a consensus target price of $49.38.

Oculis Trading Down 23.4%

The stock’s 50 day moving average price is $27.75 and its 200-day moving average price is $25.19. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1.32 billion, a PE ratio of -10.44 and a beta of 0.38.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. On average, sell-side analysts expect that Oculis Holding AG will post -2.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Institutional investors have recently bought and sold shares of the business. Gildi lifeyrissjodur bought a new position in Oculis during the fourth quarter valued at $50,250,000. Aberdeen Group plc lifted its holdings in shares of Oculis by 39.4% in the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after acquiring an additional 493,827 shares during the last quarter. Syquant Capital Sas bought a new stake in shares of Oculis in the 4th quarter worth about $3,849,000. Simplify Asset Management Inc. bought a new stake in shares of Oculis in the 4th quarter worth about $1,972,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.